Furthermore, additional studies are necessary to determine how and when targeting S100A4 in cancer synergizes with current, standard-of-care chemo, radiation, targeted, or immunotherapies such as anti-PD-1, anti-PD-L1, and anti-CTLA4, or CAR-T and other cellular therapies. The gene discussed is S100A4; the disease is cancer.